Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant for Sleep Disturbance in Veterans with PTSD
NCT03642028Phase 4Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Aug 2019
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Insomnia and post-traumatic stress disorder (PTSD) comparing Suvorexant with Placebo (2 arms). Primary endpoints: Insomnia Severity Index at 12 weeks and Clinician Administered PTSD Scale for DSM-5 at 12 weeks. Started Aug 2019; status: recruiting.
02
Drugs
suvorexant
03
Conditions
Insomniapost-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03642028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03642028.